Bunaye, Robert P. Light and Rajiv Agarwal
Pooneh Alborzi, Nina A. Patel, Carla Peterson, Jennifer E. Bills, Dagim M. Bekele, Zerihun
Randomized Double-Blind Pilot Trial
Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease : A
Print ISSN: 0194-911X. Online ISSN: 1524-4563
Copyright © 2008 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
2008;52:249-255; originally published online July 7, 2008;
World Wide Web at:
The online version of this article, along with updated information and services, is located on the
Data Supplement (unedited) at:
is online at:
Information about subscribing to
Information about reprints can be found online at:
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located,
can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Requests for permissions to reproduce figures, tables, or portions of articles originally published
by guest on June 3, 2013http://hyper.ahajournals.org/Downloaded from
effects in patients with CKD. In 1 such trial, reduction in
albuminuria from baseline to 24 weeks is the primary end
point (www.clinicaltrials.gov identifier NCT00421733),
whereas in another the change in left ventricular mass index
assessed by cardiac MRI over 48 weeks is the primary end
point (www.clinicaltrials.gov identifier NCT00497146). Both
of these trials were done in patients with CKD and should
provide better evidence (or lack thereof) for cardiovascular
and renal protection.
Sources of Funding
This work was supported by a grant from Abbott. P.A. was supported
by a fellowship grant from Amgen and N.A.P. by a training grant
from the National Institutes of Health (5T32DK062711).
R.A. serves on the speaker bureau of Abbott Pharmaceuticals and on
the steering committee of clinical trials using paricalcitol supported
by Abbott Pharmaceuticals. The remaining authors report no
1. Andress DL. Vitamin D in chronic kidney disease: a systemic role for
selective vitamin D receptor activation. Kidney Int. 2006;69:33–43.
2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA,
Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium,
and phosphorus in patients with chronic kidney disease: results of the
study to evaluate early kidney disease. Kidney Int. 2006;71:31–38.
3. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D,
Chang Y, Camargo CA Jr, Tonelli M, Thadhani R. Vitamin D levels and
early mortality among incident hemodialysis patients. Kidney Int. 2007;
4. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba
M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk
for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a
haemodialysis population. Nephrol Dial Transplant. 2004;19:179–184.
5. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.
Survival of patients undergoing hemodialysis with paricalcitol or cal-
citriol therapy. N Engl J Med. 2003;349:446–456.
6. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD,
Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD.
Survival predictability of time-varying indicators of bone disease in
maintenance hemodialysis patients. Kidney Int. 2006;70:771–780.
7. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer
KB, Johnson HK, Zager PG. Mortality risk among hemodialysis patients
receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865.
8. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D
receptor ligands. Endocr Rev. 2005;26:662–687.
9. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T,
Fukushima N, Doi T. 22-Oxacalcitriol prevents progressive glomerulo-
sclerosis without adversely affecting calcium and phosphorus metabolism
in subtotally nephrectomized rats. Nephrol Dial Transplant. 2002;17:
10. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-
Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-an-
giotensin system. J Clin Invest. 2002;110:229–238.
11. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor
DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA,
Thadhani R, Kang PM. Activated vitamin D attenuates left ventricular
abnormalities induced by dietary sodium in Dahl salt-sensitive animals.
Proc Natl Acad Sci U S A. 2007;104:16810–16815.
12. Wolf M, Thadhani R. Vitamin D in patients with renal failure: a summary
of observational mortality studies and steps moving forward. J Steroid
Biochem Mol Biol. 2007;103:487–490.
13. Levin A, Li YC. Vitamin D and its analogues: do they protect against
cardiovascular disease in patients with kidney disease? Kidney Int. 2005;
14. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG.
Using serum creatinine to estimate glomerular filtration rate: accuracy in
good health and in chronic kidney disease. Ann Intern Med. 2004;141:
15. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of Vitamin
D analogs on gene expression profiling in human coronary artery smooth
muscle cells. Atherosclerosis. 2006;186:20–28.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular filtration rate from serum creat-
inine: a new prediction equation. Modification of Diet in Renal Disease
Study Group [see comments]. Ann Intern Med. 1999;130:461–470.
17. Agarwal R. Ambulatory GFR measurement with cold iothalamate in
adults with chronic kidney disease. Am J Kidney Dis. 2003;41:752–759.
18. Agarwal R, Vasavada N, Chase SD. Liquid chromatography for
iothalamate in biological samples. J Chromatogr B Analyt Technol
Biomed Life Sci. 2003;785:345–352.
19. Agarwal R. Chromatographic estimation of iothalamate and p-aminohippuric
acid to measure glomerular filtration rate and effective renal plasma flow in
humans. J Chromatogr B Biomed Sci Appl. 1998;705:3–9.
20. Comper WD, Jerums G, Osicka TM. Differences in urinary albumin
detected by four immunoassays and high-performance liquid chromatog-
raphy. Clin Biochem. 2004;37:105–111.
21. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a gener-
alized estimating equation approach. Biometrics. 1988;44:1049–1060.
22. Huber PJ. The behavior of maximum likelihood estimates under non-
standard conditions. Proc Fifth Berkeley Symp Math Stat Prob. 1967;1:
23. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais
SJ, Metivier F. Mineral metabolism and arterial functions in end-stage
renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc
24. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC,
Stewart PM, Hewison M. Synthesis of 1,25-dihydroxyvitamin D(3) by
human endothelial cells is regulated by inflammatory cytokines: a novel
autocrine determinant of vascular cell adhesion. J Am Soc Nephrol.
M, Balling R, Lengeling A. 1alpha,25-Dihydroxyvitamin D3 is a potent
suppressor of interferon gamma-mediated macrophage activation. Blood.
26. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-
Court, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and
variation in the TIMP-1 response with VDR genotype: mechanisms for
inflammatory damage in chronic disorders? QJM. 2002;95:787–796.
27. Rostand SG. Ultraviolet light may contribute to geographic and racial
blood pressure differences. Hypertension. 1997;30:150–156.
28. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol
and blood pressure in normotensive men. Hypertension. 1997;30:
29. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger
SS, Willett WC, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk
of incident hypertension. Hypertension. 2007;49:1063–1069.
30. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a
short-term vitamin D(3) and calcium supplementation on blood pressure
and parathyroid hormone levels in elderly women. J Clin Endocrinol
31. Tian J, Liu Y, Williams LA, de Zeeuw D. Potential role of active vitamin
D in retarding the progression of chronic kidney disease. Nephrol Dial
32. Healy KD, Frahm MA, DeLuca HF. 1,25-Dihydroxyvitamin D3
up-regulates the renal vitamin D receptor through indirect gene activation
and receptor stabilization. Arch Biochem Biophys. 2005;433:466–473.
33. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz
U, Ritz E, Amann K. 1,25-Dihydroxyvitamin D3 decreases podocyte loss
and podocyte hypertrophy in the subtotally nephrectomized rat. Am J
Physiol Renal Physiol. 2004;286:F526–F533.
34. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P,
Williams L, Batlle D. Antiproteinuric effect of oral paricalcitol in chronic
kidney disease. Kidney Int. 2005;68:2823–2828.
35. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF.
Meta-analysis: vitamin D compounds in chronic kidney disease. Ann
Intern Med. 2007;147:840–853.
Alborzi et al Paricalcitol in CKD
by guest on June 3, 2013 http://hyper.ahajournals.org/Downloaded from